Neuron23, Inc.

Neuron23, Inc., is an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Founded in partnership with Origenis GmbH, Neuron23 is currently advancing multiple therapeutics addressing genetically validated targets, with lead programs against leucine-rich repeat kinase 2 (LRRK2), a gene associated with Parkinson’s disease and systemic inflammatory diseases, and tyrosine kinase 2 (TYK2), a JAK family protein that plays a role in pathological immune signaling. The prioritization of LRRK2 and TYK2 allows the company to spotlight its foundational strengths in chemistry, biology, human genetics, and AI. Neuron23 is based in South San Francisco, CA.